Abstract 956P
Background
Microvascular invasion (MVI) is closely associated with high risk of recurrence and poor long-term survival in HCC patients. For these patients, active and effective adjuvant therapy is of great significance to improve the prognosis. Therefore, we explored the efficacy and safety of interferon-α (IFN-α) combined with PD-1 monoclonal antibody (tislelizumab, TIS) as adjuvant therapy for HCC patients with MVI.
Methods
In this phase 2 study, histologically confirmed HCC patients who had undergone curative resection with MVI, Child-Pugh A, and an ECOG PS ≤1 were enrolled. Patients separately received TIS (200 mg IV Q3W) plus IFN-α (30 μg BIW) or active surveillance until disease progression, intolerable toxicity or withdrawal of consent. The primary endpoint was recurrence free survival (RFS). Secondary endpoints included overall survival (OS) and safety.
Results
From January 2021 to December 2021, TIS plus IFN-α group and active surveillance group enrolled 24 and 14 patients, respectively. Baseline characteristics were generally comparable between two groups, including MVI grade (M1: 90.0% vs 85.7%; M2: 10.0% vs 14.3%) and any tumours diameter > 5cm (65.0% vs 50.0%) in TIS plus IFN-α, respectively. At data cutoff (17 Apr 2023), RFS was not reached in TIS plus IFN-α group (95%CI: 9.8-NE), whereas in active surveillance group was 17.09 month (95%CI: 4.8-NE). 1-year RFS rate in TIS plus IFN-α and active surveillance group was 79.2% (95%CI: 0.5-0.9) and 50.0% (95%CI: 0.2-0.7), separately. Median OS was not reached in either group. No severe postoperative complications were observed. In TIS plus IFN-α group, Grade 1 or higher AEs were mainly rash (20.0%), pyrexia (15.0%), pruritus (10.0%) and diarrhea (10.0%).
Conclusions
These results suggested that HCC patients with MVI may benefit from adjuvant tislelizumab plus IFN-α, which can be tested in a future confirmatory trial. We will continue follow-up and update the data further. In the meantime, related basic experiments are underway.
Clinical trial identification
ChiCTR2000037461.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Shanghai Shenkang Hospital Development Center (No. SHDC2020CR3031B).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18